Penetration of ceftriaxone into the cerebrospinal fluid and its relationship to inflammatory markers during bacterial meningitis;Průnik ceftriaxonu do likvoru a jeho v vztah k markerům zánětu v průběhu invazivní bakteriální infekce

Klinicka Mikrobiologie a Infekcni Lekarstvi

Volumn 16, Issue 2, 2010, Pages 64-72

  Prášil, Petr ^a   Buchta, V ^b   Paterova P ^b   Hanovcova I ^b,c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c Fakulta Vojenského Zdravotnictví UO v Brn   (Czech Republic)

Author keywords

Bacterial meningitis; Blood brain barrier; Ceftriaxone; Inflammatory markers

Indexed keywords

C REACTIVE PROTEIN; CEFTRIAXONE; FIBRINOGEN; INTERLEUKIN 6;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL MENINGITIS; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; FEMALE; HUMAN; INFLAMMATION; MALE; NEISSERIA MENINGITIDIS; NEUTROPHIL COUNT; STREPTOCOCCUS PNEUMONIAE;

EID: 77953505945     PISSN: 1211264X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. htpp://www.szu.cem/epidat/epiabs-97-06.html.
2. Pícha D, Honegr K, Habanec T, Beneš J. Infekce nervového systému. In: Beneš J. (eds.): Infekční lékařství. Praha: Galén, 2009, s. 509-532.
3. nd ed. Praha: Galén, 1995.
4. Hobstová J. Hnisavé meningitidy v dětském věku. Praha: Galén, 1999.
5. Kolektiv českých a slovenských autorů. Zásady diagnostiky a racionální terapie bakteriálních meningitid. Praha: Mediforum, 1999.
6. th Edition, Philadelphia: Churchill Livingstone, 2010.
7. Scarborough M, Thwaites GE. The diagnosis and management of acute bacterial meningitis in resource - poor setting. Lancet Neurol. 2008;7(7):637-648.
8. rd ed, Praha: Panax, 1999; s.245-249.
9. Hobstová J. Jsou cefalosporiny 3. generace lékem volby u hnisavých meningitid? Klin mikrob inf lék. Praha, 2001;5(7):141-142.
10. Myslivec O, Beneš J. Průnik antibiotik do likvoru u pacientů s hnisavou meningitidou. Klin mikrob inf lék. Praha, 2001;5(7):125-130.
11. Lutsar I, Mc Cracken GH Jr, Fieldland IR. Antibiotic pharmacodynamics in cerebrospinal Fluid. Clin Inf Dis. 1998;27:1,117-129.
12. Swartz MN. Bacterial meningitis: a view of the past 90 years. N Engl J Med 2004;351:1826-1828.
13. Kim KS. Acute bacterial meningitis in infants and children. Lancet Infect Dis. 2010;10(1):32-42.
14. Spector R. Ceftriaxone pharmacokinetics in the central nervous system. J Pharmacol Exp Ther, 1996:263:380-383.
15. Schmidt T, Trauber MG. Pharmacodynamics of antibiotics in the therapy of meningitis: infection model observation. J Antimicrob Chemoter. 1993;31:61-70. (Pubitemid 23193754)
16. Spector R. Ceftriaxone transport through blood brain barrier. J Infect Dis. 1987;156:209-211. (Pubitemid 17089407)
17. Miranda J, Tunel AR. Strategies and new developments in the management of bacterial meningitis. Infect Dis Clin North Am. 2009;23(4):925-943.
18. Kearney BP, Aweeka FT. The penetration of anti-infectives into the central nervous system. Central Nerv System Infect. 1999;17:833-900.
19. Anders DR, Craig WA. Pharamacokinetics and pharmacodynamics of antibiotics in meningitis. Inf Dis North Am. 1999;13:595-618.
20. Roberts JA, Roberts MS, Robertson TA et al. Piperacillin penetration into tissue of critically ill patiens with sepsis-bolus versus continuous administration? Crit Care Med. 2009;37(3):926-933.
21. Damas P et al, Sepsis and serum cytokine concentrations. Crit Care Med. 1997;25:405-412.
22. Dilara I, Huseyn C, Idris S, Omer C. Serum C-reactive protein and interleukine levels in neonatal sepsis. Acta Medica. 2002;45:111-113.
23. Holub J. Imunitní reakce u serózních zánětů CNS. Klin mikrob inf lék. Praha, 2000;6:172-177.
24. Holub M. Imunologické aspekty sepse. Klin mikrobiol inf lék 1998;4(7):200-204.
25. th edition. New York: McGraw-Hill, 1998.
26. Stites PD, Terr AI. Základní a klinická imunologie. 1. vyd. Praha: Victoria Publishing, 1994.
27. Rosenbloom AJ, Pinsky MR, Bryant JL. Leukocyte Activation in the Peripheral Blood of Patiens with Cirrhosis of the Liver and SIRS. JAMA 1995;274:58-65.
28. Černý V, Kula R, Novák I, Cvachovec K. a kol. Sepse v intenzivní péči. Maxorf 2005.
29. De Gigo Glaría M, Mosccicati GG, Ramos RG. Determination of ceftriaxone in cerebrospinal fluid by ion-pair liquid chromatography. J AOAC Int. 2005;88(2):436-439. (Pubitemid 40479397)
30. Ashman MJ, Wildschut ED, Tibboel D et al. Microanalysis of beta-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates. Antimicrob Agents Chemother. 2009;53(1):75-80.
31. Pojar M, Mandak J. Intersticiální mikrodialýza v klinické a experimentální medicíně. Čas. Lék Čes. 2006;145:766-770.
32. Halley AJ, Lipman J, Deans R et al. Tissue accumulation of cephalotin in burns: a comparative study by microdialysis of subcutaneous interstitial fluid cephalotin concentration in burn patiens and healthy volunteers. Antimicrob Agents Chemother. 2009;53(1):210-215.
33. Pojar M, Mandak J, Malakova J et al. Tissue and plasma concentrations of antibiotics during cardiac surgery with cardiopulmonary bypass-microdialysis study. Biomed Pap Med Fac Palacky Olomouc Czech Repub. 2008;152(1):139-145.
34. Brunner M, Derendorf H, Miller M. Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. Curr Opin Pharmacol. 2005;5(5):495-459.
35. Urbášková P, a kol. Vyšetření pro antimikrobiální terapii. Praha: Avicenum, 1985.
36. Buke AC, Cavusoglu C, Karasulu E et al. Does dexamethasone effect ceftriaxone penetration into cerebrospinal fluid in adult bacterial meningitis. Int J Antimicrob Agents. 2003;21:452-456.
37. Nudelman Y, Tunkel AR. Bacterial meningitis: epidemiology, pathogenesis and management update. Drugs. 2009;69(18):2577-2596.
38. Sebire G, Cyr C, Echenne B. Benefit of glucocorticosteroid in the routine therapy of bacterial meningitis in children. Eur J Pediatr Neurol. 2006;10(4):163-166.
39. Cronin L, Cook DJ, Carlet J et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995;23:1430-1439.
40. Stuertz K, Schmidt H, Trostdorf F et al. Lower lipoteichoic and teichoic acid CSF concentrations during treatment of pneumococcal meningitis with non-bacteriolytic antibiotics than with ceftriaxone. Scand J Infect Dis 1999;31:367-370.
41. http://www.eucast.org/clinicalbreakpoints.html.
42. Giroir BP, Quint PA, Barton P et al. Preliminary evaluation of recombinant amino- terminal fragment of human bactericidal/permeability- increasing protein in children with severe meningococcal sepsis. Lancet 1997;350:1439-1443.
43. Ortolani O, Conti A, De Gaudio AR et al. The effect of glutathione and N- acetylcysteine on lipoperoxidative damage in patiens with early septic shock. Am J Respir Crit Care Med 2000;161:1907-1911. (Pubitemid 30418128)
44. Opal SM, Fisher CJ Jr, Dhainaut JF et al. The confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997;25:1115-1124.
45. Shimetani N, Shimetani K, Mori M. Levels of three inflammation markers, C-reactive protein, serum amyolid A protein and procalcitonin, in the serum and cerebrospinal fluid of patiens with meningitis. Scand J Clin Lab Invest. 2001;61(7):567-574.
46. Bernard JR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl. J. Med 2001;344:699-709.